Storia in 6 fonti

AstraZeneca sales rise as demand for cancer treatments grow

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

Raccontata da

hurriyetdailynews.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

independent.co.ukStai leggendo11 h fa

AstraZeneca sales rise as demand for cancer treatments grow

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

originale

Timeline cronologica

lunedì 27 luglio 2026·hurriyetdailynews.com
AstraZeneca quarterly net profit rises on strong cancer drug sales - Latest News
British pharmaceutical giant AstraZeneca yesterday said net profit rose in its second quarter, driven once again by strong growth in sales of its cancer drugs.
lunedì 27 luglio 2026·independent.co.uk
AstraZeneca sales rise as demand for cancer treatments grow
It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

france24.com

9 h fa

AstraZeneca profit rises on strong cancer drug sales

British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs.

Leggi questa versione → originale

euronews.com9 h fa

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales

AstraZeneca Q2 net profit +2% ($2.51bn), core EPS +18% beating consensus, on track $80bn revenue by 2030. Obesity drug elecoglipron entry marks diversification into consumer health, challenging Novo Nordisk and Eli Lilly duopoly.

Leggi questa versione → originale

hurriyetdailynews.com12 h fa

AstraZeneca quarterly net profit rises on strong cancer drug sales - Latest News

AstraZeneca Q2 profit +2% to $2.5B, revenue +6% to $15.4B, powered by oncology-drug sales; $80B revenue target by 2030 reconfirmed. Entry into high-value GLP-1 weight-loss market and 20+ pipeline readouts in 18 months signal growth momentum; Wainua trial failure contained risk.

Leggi questa versione → originale

benzinga.com7 h fa

What's Going on With AstraZeneca Stock Monday? - AstraZeneca (NYSE:AZN)

AstraZeneca beat Q2 EPS ($2.63 vs $2.48) but missed revenue; oncology portfolio grew 16% to $7.33B. Trial failures on Ultomiris and Sone-Ve highlight R&D execution risk; however, 20+ pipeline readouts over next 18 months validate continued biotech investment thesis.

Leggi questa versione → originale

it.euronews.com9 h fa

AstraZeneca, utile trimestrale +2% grazie alle vendite di farmaci oncologici

AstraZeneca Q2 2026: +2% utile (2,51B$), +5% ricavi (15,38B$) da oncology. Target 80B$ 2030 confermato; 20+ trial results attesi in 18 mesi. Espansione in obesity drugs (elecoglipron) per scalare vs Novo Nordisk/Eli Lilly segnala consolidamento pharma; pipeline intensity richiede IT infrastructure data-intensive, driver di budget tech healthcare 2026-30.

Leggi questa versione → originale

lunedì 27 luglio 2026·

independent.co.uk

AstraZeneca sales boosted by soaring demand for cancer treatments

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

lunedì 27 luglio 2026·

euronews.com

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales

Strong cancer drug sales lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, helping the company maintain its 2026 outlook.

lunedì 27 luglio 2026·

it.euronews.com

Utile netto trimestrale AstraZeneca +2% grazie alle forti vendite di farmaci oncologici

Le robuste vendite dei farmaci oncologici hanno spinto gli utili del secondo trimestre del colosso farmaceutico anglo-svedese AstraZeneca oltre le attese, consentendo al gruppo di…

lunedì 27 luglio 2026·

it.euronews.com

AstraZeneca, utile trimestrale +2% grazie alle vendite di farmaci oncologici

Le robuste vendite dei farmaci oncologici hanno spinto gli utili del secondo trimestre del colosso farmaceutico anglo-svedese AstraZeneca oltre le attese, permettendo al gruppo di…

lunedì 27 luglio 2026·

france24.com

AstraZeneca profit rises on strong cancer drug sales

British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs.

lunedì 27 luglio 2026·

benzinga.com

What's Going on With AstraZeneca Stock Monday? - AstraZeneca (NYSE:AZN)

AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.